Sepsis – Pipeline Review, H2 2018
- Pages: 278
- Published: July 2018
- Report Code: GMDHC10619IDB
Global Markets Direct’s, ‘Sepsis – Pipeline Review, H2 2018’, provides an overview of the Sepsis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Sepsis
– The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects
– The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Sepsis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sepsis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Adrenomed AG
Am-Pharma BV
Arch Biopartners Inc
Asahi Kasei Corp
Atox Bio Ltd
Aurigene Discovery Technologies Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cell2B Advanced Therapeutics SA
Cells for Cells SA
Chiome Bioscience Inc
Cilian AG
Cynata Therapeutics Ltd
CytaCoat AB
Dr. Franz Kohler Chemie GmbH
Endacea Inc
Enlivex Therapeutics Ltd
Evec Inc
Expression Drug Designs LLC
Immunwork Inc
InflaRx NV
Integrated BioTherapeutics Inc
Lead Discovery Center GmbH
Mochida Pharmaceutical Co Ltd
Nosopharm SAS
OncoImmune Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
ProThera Biologics Inc
Ra Pharmaceuticals Inc
Recce Ltd
Ribomic Inc
Rimonyx Pharmaceuticals Ltd
SciClone Pharmaceuticals Inc
SetLance srl
Shionogi & Co Ltd
Sirtex Medical Ltd
SK Biopharmaceuticals Co Ltd
Syntiron LLC
Takeda Pharmaceutical Co Ltd
Therakind Ltd
Therashock LLC
TiGenix NV
Vascular BioSciences
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.